<DOC>
	<DOCNO>NCT00180011</DOCNO>
	<brief_summary>This study randomize , placebo control , double blind study measure safety efficacy new , injectable asthma medication , omalizumab , group minority moderate severe asthma adequately control use inhaled oral steroid . Primary endpont change asthma symptom utility index . Secondary endpoint change asthma Quality life , asthma exacerbation rate , lung function 12 week treatment period .</brief_summary>
	<brief_title>Efficacy Omalizumab Add Therapy Minority Patients With Moderate Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Age 1830 Minority Patients Moderate Severe allergic asthma ( defined National Asthma Education Prevention Guidelines ( 7 ) ] . Allergic asthma define elevated IgE level ( &gt; 100 IU/ml ) skin test sensitivity least one common aeroallergen asthma control score great 1.5 ( 5 ) randomization visit use equivalent least 1000 mcg fluticasone daily systemic steroid use FEV1 5090 % predict screen randomization visit Active smoking within one year and/or great 10pack year history smoke Women childbearing age must use effective contraception Malignancy diagnose within past 5 year Underlying lung disease asthma Inability comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>omalizumab</keyword>
	<keyword>severe asthma</keyword>
	<keyword>moderate asthma</keyword>
	<keyword>injectable asthma medication</keyword>
	<keyword>Xolair</keyword>
</DOC>